Lys Therapeutics

Lys Therapeutics: Develops first-in-class antibody therapies for severe neurological diseases. BioTech · Series A · Caen, France. Rated 61/100 on Startup24.

Develops first-in-class antibody therapies for severe neurological diseases.

Preliminary profile · public data only

Startup24 listed Lys Therapeutics from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

Startup24 rating: 61/100

Lys Therapeutics has a differentiated intravascular antibody thesis and a lead asset, LYS241, described as approaching Phase 1a/1b across significant neurological indications.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.